Japan · Delayed Price · Currency is JPY BrightPath Biotherapeutics Company Description
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan.
The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers.
In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1223 to target blood cancers.
The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017.
BrightPath Biotherapeutics Co., Ltd. was incorporated in 2003 and is headquartered in Kawasaki, Japan.
| Country | Japan |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Kenichi Nagai |
Contact Details
Address: Kanagawa Prefecture Kawasaki , Tokyo Tokyo Japan | |
| Phone | 81 4 4440 3939 |
| Website | brightpathbio.com |
Stock Details
| Ticker Symbol | 4594 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3274140007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kenichi Nagai | Chief Executive Officer |
| Yoichi Takeshita | Chief Financial Officer |